A377740 Stock Overview
Manufactures and sells in-vitro diagnostic animal medicines in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
BioNote, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,065.00 |
| 52 Week High | ₩6,460.00 |
| 52 Week Low | ₩3,800.00 |
| Beta | 0 |
| 11 Month Change | -1.34% |
| 3 Month Change | -0.97% |
| 1 Year Change | -16.01% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.83% |
Recent News & Updates
Shareholder Returns
| A377740 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.6% | -0.09% | -0.05% |
| 1Y | -16.0% | 20.1% | 6.0% |
Return vs Industry: A377740 underperformed the KR Biotechs industry which returned 22.1% over the past year.
Return vs Market: A377740 underperformed the KR Market which returned 5% over the past year.
Price Volatility
| A377740 volatility | |
|---|---|
| A377740 Average Weekly Movement | 2.1% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A377740 has not had significant price volatility in the past 3 months.
Volatility Over Time: A377740's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 313 | n/a | www.bionote.co.kr |
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-contents reagents.
BioNote, Inc. Fundamentals Summary
| A377740 fundamental statistics | |
|---|---|
| Market cap | ₩416.39b |
| Earnings (TTM) | ₩19.17b |
| Revenue (TTM) | ₩94.22b |
21.6x
P/E Ratio4.4x
P/S RatioIs A377740 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A377740 income statement (TTM) | |
|---|---|
| Revenue | ₩94.22b |
| Cost of Revenue | ₩102.91b |
| Gross Profit | -₩8.69b |
| Other Expenses | -₩27.86b |
| Earnings | ₩19.17b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 187.87 |
| Gross Margin | -9.22% |
| Net Profit Margin | 20.35% |
| Debt/Equity Ratio | 0% |
How did A377740 perform over the long term?
See historical performance and comparison